Professor Ray Powles CBE

Qualifications

CBE MB BS BSc MD FRCP FRCPath

GMC number: 1632655

Practising since: 1964

Specialties

Haematology, Medical Oncology

Consultation times

  • 11:00am - 3:00pm, Monday - Friday

About

Prof Ray Powles trained at St Bartholomew’s Hospital and first worked as a junior doctor in 1965 on a leukaemia unit at a time when the disease was virtually untreatable, all patients succumbing usually in days or a few weeks. He then moved to the Royal Marsden in 1969 where he worked until 2004. He initially was involved in defining the use of active specific immunotherapy for acute myeloblastic leukaemia at a time of the Nixon era of looking for immunological approaches to ‘beat cancer’. As a part of this programme, he was given the fourth blood Cell Separator worldwide costing the equivalent of £500k to make the vaccine, showed, and reported in 1972, the first use of this machine for plasma exchange in myeloma. He was subsequently invited by Jan Waldenstrom to give a seminar in Malmo in 1972. In 1973 he led the team responsible for the first successful allogeneic Bone Marrow Transplant in Europe undertaken in 1973. In the early 80’s he was also the first to use cyclosporine and parental acyclovir and took both of these drugs through from first patient to approval, prior to use in the US. He, with Tim MacElwain, reported the first use of autologous Stem Cell transplant for myeloma in the Lancet in 1983. He was at the forefront of the use of haemopoietic growth factors and was particularly involved in the licensing of GM-CSF. All of these developments have for three decades been part of routine evidence-based clinical practice. Following the untimely death of Tim McElwain he ran the Royal Marsden Hospital Myeloma Unit and created the RMH prospective myeloma database that was the basis of consistently allowing the RMH to dominate peer-reviewed presentations at ASH most years.

He now runs a Haemato-oncology Unit in the private sector at Cancer Centre London, at Parkside, Wimbledon.

He was a Panel member of the Independent Reconfiguration Panel from 2003 to 2013, an advisory non-departmental public body (NDPB) that advises the Secretary of State for Health on contested proposed reconfigurations.

In 2002 Ray founded and became Chairman of the European Blood and Marrow Transplant (EBMT) Nuclear Accident Committee, a network of 500 centres throughout Europe that has harmonized EU and US care and training if a large radiation incident occurred, particularly if terrorists initiated. He has been a member since 2009 of the Emergency Preparedness Clinical Leadership Advisory Group (EPCLAG) of the UK Dept of Health, to advise on Radiation Emergencies

Ray was a trustee until recently of the health policy parliamentary advice group, the New Health Network, and was a Member in 2002 of the Cabinet Office Public sector team for streamlining Healthcare Inspections. He also was a member of the 2008 NHS Leadership Workstream panel.

Between 2000 and 2008 he was a Director, and Board member of the Swiss Biopharmaceutical Company BioPartners, which became the first Company ( simultaneously with Sandoz) to have approved by EMEA a biosimilar drug hGh growth hormone.

He formed and was the first Chairman until Dec 2010 of the American Society of Haematology (ASH) Scientific Committee for Plasma Cell Biology, having previously been Chairman of the ASH Haemopoetic Growth Factor Scientific Committee. He is on the Scientific Advisory Board of the International Myeloma Working Group.

He is a founding Patron of a new Indian charity New Indian Cancer Care Initiative (NICCI) that was launched at the British High Commission in Dehli in Nov 2010. He has been a Medical Advisor to the Bud Flanagan Leukaemia Charity, and AmeriCares India Advisory Board Member since 2008. For the last 4 years, he has been a Trustee of the Russian Children’s Leukaemia Charity ‘Gift of Life’.

He has written 1200 scientific articles, abstracts and over 250 peer-reviewed papers; and lectures on the International circuit.

In 1999 he was given a Lifetime Achievement Award by the Indian Cancer Patients Aid Association for his work in training and facilitating Cancer care.

Prof Ray Powles only sees adults.

Special interests

Myeloma, Waldenstrom's Macroglobulinemia, MGUS Chronic Lymphocytic Leukaemia, Low-grade lymphomas.

Personal interests

Tennis, football and cricket. Reading, film and theatre. Cooking.

Locations Professor Ray Powles CBE works with

Related experience

Research

  • 1200 publications.
  • Currently primarily myeloma Real-World data bases. Artificial Intelligence in medicine

Memberships

  • RCP RCPath IMWG EBMT

Insurers Professor Ray Powles CBE works with

Professor Ray Powles CBE works with the following private medical insurance providers:

  • Allianz
  • Aviva Health
  • AXA Health
  • AXA - Global Healthcare
  • Bupa
  • Bupa Global
  • Bupa On Demand
  • Cigna
  • Cigna International
  • CS Healthcare
  • InterGlobal
  • SAGA
  • Standard Life
  • Vitality Health (Pru Health)
  • WPA

Declaration

Professor Ray Powles CBE does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.

Professor Ray Powles CBE does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.

Professor Ray Powles CBE does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.

Ask a question about this consultant

Fill in the form below and we'll get back to you within one working day. If it's urgent, you can call us on 020 8247 3351.

Thank you

A member of the team will respond to you soon.

To continue to receive communications from Nuffield Health about our exclusive offers, products and services, then please tell us how you'd like to be contacted by ticking the relevant boxes below:

On occasion Nuffield Health may contact you with pertinent service information in regards to services we provide. Note that you can either amend or withdraw your consent at any time.

For information about where your personal data may be processed, how it may be processed and for details of our Data Protection Officer, please see our Privacy Policy.